Ivonescimab联合化疗在中国获得NMPA批准，用于基于HARMONi的2L+EGFRm NSCLC——一项临床试验：观察到Ivonescinab联合化疗的总生存率呈阳性趋势-动脉橙

Ivonescimab联合化疗在中国获得NMPA批准，用于基于HARMONi的2L+EGFRm NSCLC——一项临床试验：观察到Ivonescinab联合化疗的总生存率呈阳性趋势

2024-06-01 businesswire 等2家媒体报道产品获批





Summit Therapeutics宣布，其合作伙伴Akeso Inc.根据III期HARMONi-a阳性试验结果，获得了PD-1/VEGF双特异性抗体ivonescimab在中国的上市许可。该研究评估了ivonescimab联合铂类双联化疗治疗EGFR突变，局部晚期或转移性NSCLC患者，这些患者在EGFR TKI治疗后进展。该人群先前在PD-1单克隆抗体的III期试验中未成功。该批准是这种差异化治疗的重要里程碑。（摘要由动脉网AI生成）

2024-05-31 Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

businesswire
2024-06-01 Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

CISION